학술논문
EE152 Cost-Effectiveness Modeling of Lurbinectedin As a Second-Line Therapy in Patients with Small Cell Lung Cancer (SCLC)
Document Type
Abstract
Author
Source
In Value in Health June 2023 26(6) Supplement:S87-S87
Subject
Language
ISSN
1098-3015